<DOC>
	<DOCNO>NCT00472693</DOCNO>
	<brief_summary>The purpose study determine whether addition bevacizumab Abraxane second-line therapy Her-2 negative , hormone receptor negative metastatic breast cancer .</brief_summary>
	<brief_title>Bevacizumab Abraxane Second-line Therapy Triple Negative Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>Female , age 18 year older able give inform consent . Histologically cytologicallyproven adenocarcinoma breast time first diagnosis ECOG performance status 0 1 Life expectancy &gt; 12 week Stage IV disease least one lesion measurable standard RECIST criterion Disease progression least one prior chemotherapy regimen metastatic disease within 12 month adjuvant chemotherapy initiation . All chemotherapy must stop &gt; 2 week enrollment . Primary metastatic tumor must negative estrogen progesterone receptor expression . Testing must do CLIAapproved laboratory . Primary metastatic tumor must 0 1+ stain HER2/neu identify immunohistochemically ( IHC ) , approve method use one standard monoclonal polyclonal antibody ( HercepTest , cb11 , PAb1 , TAB250 ) , FISH status know , must negative . Testing must do CLIAapproved laboratory . Left ventricular ejection fraction must &gt; = institutional low limit normal determine MUGA echocardiogram Patient must able comply treatment followup procedure : Adequate bone marrow , liver renal function ; Absolute neutrophil count &gt; = 1500/mm3 ; Hemoglobin &gt; = 10 g/dl ; Platelet count &gt; = 100,000/mm3 ; Creatinine &lt; = 2.0 ; PTT either INR PT &lt; 1.5x normal ; Total bilirubin &lt; = 1.5 X upper limit normal ; AST , ALT , alkaline phosphatase &lt; = 2 X upper limit normal ( &lt; = 5X upper limit normal know liver metastasis ) If female childbearing potential , pregnancy test must negative patient must willing use effective contraception treatment least 3 month last dose study medication Prior treatment VEGF target therapy Prior taxane therapy metastatic disease adjuvant therapy within previous 12 month History prior cancer , exclude carcinoma situ cervix nonmelanoma skin cancer Known CNS disease Inadequately control hypertension ( define systolic blood pressure &gt; 150 and/or diastolic blood pressure &gt; 100 mmHg antihypertensive medication ) Any prior history hypertensive crisis hypertensive encephalopathy New York Heart Association ( NYHA ) Grade II great congestive heart failure History myocardial infarction unstable angina within 6 month prior study enrollment History stroke transient ischemic attack within 6 month prior study enrollment Significant vascular disease ( e.g. , aortic aneurysm , aortic dissection ) Symptomatic peripheral vascular disease Evidence bleed diathesis coagulopathy Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study enrollment anticipation need major surgical procedure course study Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior study enrollment History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior study enrollment Serious , nonhealing wound , ulcer bone fracture Proteinuria screening demonstrate either : Urine protein : creatinine ( UPC ) ratio &gt; 1.0 screening OR Urine dipstick proteinuria &gt; 2+ ( patient discover &gt; 2+ proteinuria dipstick urinalysis baseline undergo 24hour urine collection must demonstrate &lt; 1g protein 24 hour eligible ) Patients active infection Women pregnant lactating Radiation therapy within 3 week study entry Patients hypersensitivity ABI007 , Chinese hamster ovary cell product , recombinant human antibody Baseline neuropathy &gt; grade 2 Participation investigational study antineoplastic agent within 4 week first infusion study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Second-Line Therapy</keyword>
	<keyword>Triple Negative</keyword>
	<keyword>Her-2 negative</keyword>
	<keyword>Hormone receptor negative</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Bevacizumab</keyword>
</DOC>